HighVista Strategies’s Aclaris Therapeutics ACRS Stock Holding History

HighVista Strategies’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-86,103	Closed	-$893K	–	133
2023 Q2	$893K	Sell	86,103 -111,700	-56%	-$1.01M	0.41%	58
2023 Q1	$1.6M	Buy	197,803 +10,184	+5%	+$129K	1.3%	29
2022 Q4	$2.95M	Sell	187,619 -30,199	-14%	-$486K	1.75%	13
2022 Q3	$3.43M	Buy	217,818 +290	+0.1%	+$4.57K	1.96%	13
2022 Q2	$3.04M	Buy	217,528 +59,285	+37%	+$831K	1.83%	14
2022 Q1	$2.73M	Buy	158,243 +46,083	+41%	+$629K	1.73%	16
2021 Q4	$1.63M	Buy	112,160 +19,160	+21%	+$290K	1.3%	18
2021 Q3	$1.68M	Buy	93,000 +53,325	+134%	+$855K	1.11%	15
2021 Q2	$697K	Buy	+39,675	New	+$901K	0.49%	63

Other funds holding ACRS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighVista Strategies's ACRS Position: Q3 2023 in Review

HighVista Strategies sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 86,103 shares — an estimated $893K sold.

HighVista Strategies first reported a position in ACRS in Q2 2021 and held it in 9 quarters. The position peaked at $3.43M in Q3 2022. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

HighVista Strategies reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
HighVista Strategies sold 86,103 Aclaris Therapeutics shares in Q3 2023, an estimated $893K.
HighVista Strategies first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 9 quarters.
HighVista Strategies's Aclaris Therapeutics position peaked at $3.43M in Q3 2022.
137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.